Authorization

QIAGEN and Illumina Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests

Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management.


The agreement grants QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illuminaa??s MiSeqa?? Dx and NextSeqa?? 550Dx Systems. The agreement also includes rights for expansion of the partnership on future Illumina diagnostic (Dx) systems. Both partners are also exploring opportunities for QIAGEN to develop and market companion diagnostics based on Illuminaa??s TruSight Oncology (TSO) assays that enable comprehensive genomic profiling of tumor samples in immunotherapy.


Illumina and QIAGEN will cooperate to commercialize a menu of clinically validated workflows that combine QIAGENa??s proprietary content and bioinformatics solutions. The partnership will initially focus on commercializing oncology IVD kits to support patient management and may expand in the future to include additional clinical diagnostic fields, such as cardiology, hereditary diseases, infectious diseases, as well as inflammatory and autoimmune diseases.


"We are committed to expanding the range of clinical use cases addressed by genomic sequencing by enabling partners to deliver IVD tests and companion diagnostics on Illuminaa??s Dx instruments,a?? said Francis deSouza, CEO of Illumina. "Our partnership with QIAGEN will complement Illuminaa??s TSO 500 family with additional testing menu options, accelerating NGS adoption in oncology patient management.a??
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2020    »
ПнВтСрЧтПтСбВс
 12
3456789
10111213141516
17181920212223
242526272829